Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

124.51 -2.44 (-1.92%)
Streaming Delayed Price Updated: 2:57 PM EDT, Sep 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,391,988
Open 125.60
Bid (Size) 124.49 (2)
Ask (Size) 124.51 (1)
Prev. Close 126.95
Today's Range 123.98 - 125.62
52wk Range 86.96 - 148.15
Shares Outstanding N/A
Dividend Yield 1.42%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Novo Nordisk And Evotec Collaborate On Stem Cell-Based Therapy Development
Evotec and Novo Nordisk have partnered to develop off-the-shelf cell therapy products. The collaboration will focus on advancing stem cell-based therapies for potential commercialization. 
Via Benzinga
Forget Novo Nordisk, Buy This Magnificent Dividend Stock Instead
Even the mighty Novo Nordisk can't hold a candle to its peer in this area. 
Via The Motley Fool

Performance

YTD
+21.94%
+21.94%
1 Month
-7.97%
-7.97%
3 Month
-13.34%
-13.34%
6 Month
-2.76%
-2.76%
1 Year
+35.65%
+35.65%

More News

Read More
EXCLUSIVE: Vivani Medical Advances Its Obesity Treatment Implant With New Clinical Trial in Australia
Via Benzinga
Novo Nordisk's $600 Million Gambit Could Be a Game Changer for the Stock. Here's Why.
Via The Motley Fool
Lose Weight With Novo Nordisk Drugs, Gain Money With Stock
Via Benzinga
Novo Nordisk's Options: A Look at What the Big Money is Thinking
Via Benzinga
Novo Nordisk's Options: A Look at What the Big Money is Thinking
Via Benzinga
Popular Ozempic May Have New Use As Semaglutide Drugs Linked To Reduced Overdose Risk In Diabetic Opioid Users
Via Benzinga
Can Novo Nordisk's Weight Loss Drug Ozempic Help Stem The Devastating Addiction Crisis? New Research Says Yes
Via Benzinga
Bristol Myers-2seventy Bio Halt Phase 3 Trial For Abecma In Newly Diagnosed Myeloma Patients, Speeds Path To Profitability
Via Benzinga
Exposures Product Safety
EXCLUSIVE: Novo Nordisk Faces Political Heat Over Weight-Loss Drug Prices Ahead Of Elections, Yet 'The Real Issue Is With The Middlemen'
Via Benzinga
Novo Nordisk To Consider Ways For Patients To Affordably Access Weight Loss Drugs Ozempic, Wegovy, Says CEO
Via Benzinga
Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Via MarketBeat
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer
From Aligos Therapeutics
Via GlobeNewswire
'Miracle' Weight Loss Drug Ozempic To Enter US Price Negotiations Within A Year, Novo Nordisk CEO Says Ahead Of Senate Hearing
Via Benzinga
2 Weight-Loss Stocks That Could Rocket Higher This Year
Via The Motley Fool
Nasdaq-Traded Cannabinoid Biotech Corbus Pharma Stock Plunges 60%, But Analysts Say 'Buy The Dip' Now
Via Benzinga
Novo Nordisk CEO To Face Senate Scrutiny Over High Ozempic And Wegovy Prices, Hearing Scheduled On Tuesday
Via Benzinga
Bernie Sanders Questions Why Your Monthly Ozempic Prescription Costs More Than A Luxury Handbag When It Can Be Sold For Less Than $100
Via Benzinga
Novo Nordisk, Chewy And FedEx Are Among Top 10 Large Cap Losers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?
Via Benzinga
3 Stocks That Could Rise on European Bank Interest Rate Cuts
Via MarketBeat
Topics Economy
Exposures Interest Rates
Netflix, Eli Lilly Lead 5 Fast Growers Near Buy Points
Via Investor's Business Daily
Why Novo Nordisk Stock Fell While Eli Lilly and Viking Therapeutics Bumped Higher Today
Via The Motley Fool
US Federal Trade Commission Sues CVS Health, Cigna, UnitedHealth's Pharmacy Benefit Managers For Inflating Insulin Prices
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Novo Nordisk's Monlunabant Data Drags Stocks Of Smaller Players
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.